Clinical Trial Update: DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9) [Phase 2]

View source ↗

Summary

Phase 2 trial TAi-SHAN9 evaluating DZD8586 in relapsed or refractory diffuse large B-cell lymphoma is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• DZD8586

Snippet

Sponsor: Dizal Pharmaceuticals | Conditions: Diffuse Large B Cell Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING